Market closed
vTv Therapeutics/$VTVT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About vTv Therapeutics
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
Ticker
$VTVT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
16
Website
vTv Therapeutics Metrics
BasicAdvanced
$46M
-
-$7.01
0.66
-
Price and volume
Market cap
$46M
Beta
0.66
52-week high
$30.99
52-week low
$12.12
Average daily volume
36K
Financial strength
Current ratio
6.687
Quick ratio
6.522
Long term debt to equity
0.179
Total debt to equity
1.189
Interest coverage (TTM)
-3,427.86%
Management effectiveness
Return on assets (TTM)
-51.64%
Return on equity (TTM)
-1,335.04%
Valuation
Price to revenue (TTM)
45.989
Price to book
3.06
Price to tangible book (TTM)
3.06
Price to free cash flow (TTM)
-1.966
Growth
Revenue change (TTM)
11,011.11%
Earnings per share change (TTM)
-30.91%
3-year revenue growth (CAGR)
-54.18%
3-year earnings per share growth (CAGR)
27.45%
What the Analysts think about vTv Therapeutics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for vTv Therapeutics stock.
vTv Therapeutics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
vTv Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
vTv Therapeutics News
AllArticlesVideos
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
GlobeNewsWire·2 days ago
FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges
Benzinga·5 days ago
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for vTv Therapeutics stock?
vTv Therapeutics (VTVT) has a market cap of $46M as of March 22, 2025.
What is the P/E ratio for vTv Therapeutics stock?
The price to earnings (P/E) ratio for vTv Therapeutics (VTVT) stock is 0 as of March 22, 2025.
Does vTv Therapeutics stock pay dividends?
No, vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders as of March 22, 2025.
When is the next vTv Therapeutics dividend payment date?
vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders.
What is the beta indicator for vTv Therapeutics?
vTv Therapeutics (VTVT) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.